This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Laughter therapy in the management of dry eyes

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

In a randomised controlled trial (n=299, China)

  • laughter exercise was non-inferior to 0.1% sodium hyaluronic acid in relieving subjective symptoms at 8 weeks (mean change ocular surface disease index score:−10.5 vs −8.83 points, respectively, mean difference −1.45, 95% CI−5.08 to 2.19; p=0.43)
  • participants in the control group applied artificial tears, 0.1% sodium hyaluronic acid eyedrops, to both eyes four times daily for eight weeks
  • drawing from previously established methods of laughter therapy, researchers adapted and developed the laughter exercise to optimally engage the ocular muscles of participants, who were instructed to perform the exercise four times daily for eight weeks
    • at the baseline visit, a video showed the execution of the exercise
      • specifically, laughter exercise required them to vocalise and repeat the phrases as “Hee hee hee, hah hah hah, cheese cheese cheese, cheek cheek cheek, hah hah hah hah hah hah” 30 rounds each time, lasting for at least five minutes

Reference:

  1. Li J, Liao Y, Zhang S, Jin L, Congdon N, Fan Z et al. Effect of laughter exercise versus 0.1% sodium hyaluronic acid on ocular surface discomfort in dry eye disease: non-inferiority randomised controlled trial. BMJ 2024; 386:e080474

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.